During Day 1 of Coupa INSPIRE’15, the premier cloud spend management industry gathering of the year, Coupa Software disclosed key performance metrics demonstrating its record-breaking customer and business success in Q1 FY2015. In a separate press release, Coupa also announced today the appointment of Todd Ford as the company’s new CFO, effective immediately.

NEW YORK--(BUSINESS WIRE)-- CA Technologies (NASDAQ:CA) today announced it has signed a definitive agreement to acquire Rally Software Development Corp. (NYSE:RALY), a leading provider of Agile development software and services, for $19.50 per share, which equates to approximately $480 million, net of cash acquired. The transaction has been unanimously approved by both Boards of Directors, and is expected to close in the second quarter of CA's fiscal 2016. Based in Boulder, CO, Rally has approximately 500 employees across four continents and FY 2015 sales of $88 million.

Emeryville, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc.
(Nasdaq: ADMS) today announced that the Food and Drug Administration (FDA) has granted
orphan drug status to ADS-5102 for the treatment of levodopa-induced dyskinesia associated
with Parkinson’s disease. Adamas currently has multiple Phase 3 studies underway evaluating
ADS-5102 for this indication, which currently has no FDA-approved treatment options.

MADISON, N.J., March 10, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of Neurome™, a whole exome sequencing service designed to aid the diagnosis of rare neurological disorders in pediatric populations. Personalis, Inc., a leading genomics-based diagnostic laboratory, developed and performs the lab-developed test exclusively for Quest Diagnostics.